Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of vorinostat in a murine model of polycythemia vera

10 Mar 2012

Abstract excerpt

The discovery of the JAK2V617F mutation in most patients with Ph-negative myeloproliferative neoplasms has led to the development of JAK2 kinase inhibitors. However, JAK2 inhibitor therapy has shown limited efficacy and dose-limiting hematopoietic toxicities in clinical trials. In the present study, we describe the effects of vorinostat, a small-molecule inhibitor of histone deacetylase, against cells expressing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22408262
DOI: 10.1182/blood-2011-02-336743

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of vorinostat in a murine model of polycythemia veraPMID 22408262Read ↗

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.Semantic proximity Read ↗

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like diseaseSemantic proximity Read ↗

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.Semantic proximity Read ↗

Givinostat: an emerging treatment for polycythemia vera.Semantic proximity Read ↗

Linezolid Acts as a Selective Inhibitor of the JAK2 <sup>V617F</sup> MutationSemantic proximity Read ↗

Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.Semantic proximity Read ↗

Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.Semantic proximity Read ↗

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617FSemantic proximity Read ↗

JAK2 inhibitors: are they the solution?Semantic proximity Read ↗

Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice.Semantic proximity Read ↗

Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular MechanismsSemantic proximity Read ↗

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.